Positive Atopic Dermatitis Data On Lilly's Newly-Approved Olumiant
Just Received European Green Light For Skin Disorder
It has gone under the radar that Eli Lilly and Incyte's Olumiant has recently become the first JAK inhibitor to be approved anywhere for atopic dermatitis and the companies have been touting promising long-term data on the therapy as it expands beyond rheumatoid arthritis.
You may also be interested in...
Lilly Says Safety Not A Factor In Dropping Lupus Development With Olumiant
The pharma also warns that an FDA complete response letter could be coming for its supplemental NDA to add atopic dermatitis to the JAK1 inhibitor’s label.
Amgen/KK’s Atopic Dermatitis Deal Shows OX40’s Allure, But Market Still Tough
Amgen said Phase II data are planned for the EADV 2021 meeting, but KHK4083 will need a strong showing.
Incyte Taps Wide-Open Vitiligo Market With Positive Ruxolitinib Results
Dermatologists have compared the current market for vitiligo to that of psoriasis 30 years ago, which grew from one with a dearth of therapies to one worth about $8bn.